The early approval of the $2 billion cash infusion from Scotiabank by the Fed is a significant positive development for KeyCorp, as it not only strengthens its financial position but also boosts investor confidence, leading to a rise in its stock price. The analyst's positive outlook on future deal-making further supports the potential for continued stock appreciation.